Intimation regarding receipt of observation letter from BSE Limited dated May 06,2026 in relation to the scheme of Arrangement.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Privi Speciality Chemicals Ltd has received a 'no objection' observation letter from BSE Limited dated May 6, 2026, for the proposed scheme of amalgamation. The scheme involves the merger of two wholly-owned subsidiaries - Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited - into Privi Speciality Chemicals Ltd (the listed entity). The amalgamation is being undertaken under Sections 230-232 of the Companies Act, 2013. This regulatory approval from BSE is a key step forward for the consolidation, though the scheme remains subject to other applicable regulatory and statutory approvals including NCLT approval.
For shareholders, this consolidation of subsidiaries into the listed entity may lead to simplified corporate structure and potential operational efficiencies. The BSE's 'no objection' removes a key regulatory hurdle, though completion awaits further approvals.